Kilpest India investor presentation is published and can be accessed through the link provided below.
Excerpts:
- While the #s show a steep downward trend they have the disclaimer that COVID19 sales should be discounted
- Q1FY23 Revenue of 942.51L can be compared to Q1FY20 revenue of 324.21 to see the growth trajectory. The # of products have doubled to 100 in the last 4 years
- While the company has been talking about NSE listing for quite sometimes, there is no timelines mentioned in this investor presentation as well.
I believe a rerating can happen only when they shift their focus into diagnostic care fully and convince the market to stop looking them as an Agri player (minimum contribution to the overall sales figures)
Subscribe To Our Free Newsletter |